Abstract: The present invention relates to a novel pyrrole derivative which shows an inhibitory activity against farnesyl transferase or pharmaceutically acceptable salts or isomers thereof; to a process for preparation of said compound; and to a pharmaceutical composition such as anti-cancer composition, etc. comprising said compound as an active ingredient together with pharmaceutically acceptable carrier.

Abstract: A device for perutaneous treatment by a serotonin receptor antagonist, comprising at least three layers including A) a drug-impermeable backing layer, B) a drug storage layer provided between the packing layer and a drug release layer and containing serotonin receptor antagonist, and C) a drug release layer constituted of a pressure-sensitive adhesive layer capable of controlling the release of a drug.

Abstract: The present invention relates to a novel imidazole derivative represented by formula (1) which shows an inhibitory activity against farnesyl transferase or pharmaceutically acceptable salts or isomers thereof, in which A, n1 and Y are defined in the specification; to a process for preparation of the compound of formula (1); to intermediates which are used in the preparation of the compound of formula (1): and to a pharmaceutical composition comprising the compound of formula (1) as an active ingredient.

Abstract: Disclosed is a pharmaceutical composition comprising (E)-3,5-dihydroxy-7-[4′-4″-fluorophenyl-2′-cyclopropyl-quinolin-3′-yl]-6-heptenoic acid, or its salt or ester, of which the aqueous solution or dispersion has pH of from 6.8 to 8. The composition has good time-dependent stability and has no change in its outward appearance even after having been stored long.

Abstract: A process is provided for repairing a defect applied in producing a liquid crystal display, wherein the liquid crystal display includes a repair circuit structure, and at least one color filter and a liquid crystal formed on a front thereof. The process includes steps of (a) providing a laser having a wavelength of infrared spectrum, and (b) welding the repair circuit from a back of the liquid crystal display by the laser to repair the defect.

Abstract: This invention relates to new photoacid generator compounds and photoresist compositions that comprise such compounds. In particular, the invention relates to photoacid generator compounds that generate an anthracene acid upon exposure to activating radiation, particularly anthracene sulfonic acids such as acids that include 9,10-dialkoxyanthracene-2-sulfonate moieties. Positive- and negative-acting chemically amplified resists that contain such PAGs and that are imaged with I-line (365 nm) radiation are particularly preferred.

Abstract: The present invention provides improved medical introducer devices which incorporate a single or multi-layer PTFE peelable sheath. Devices of the present invention are suitable for use in inserting an ancilliary medical device, e.g., a catheter, guide wire and the like, into a patient. Methods of the present invention also are disclosed which employ a precision sintering process in order to produce sheaths having excellent tear properties and optimal peelability.

Abstract: The present invention relates to a pharmaceutical composition which is appropriate for eradication or extermination of Helicobacter pylori wherein [4-[4-(4-methylbenzyloxycarbonyl)phenyl[phenyl trans-4-guanidinomethylcyclohexanecarboxylate or an acid addition salt thereof are compounded and it also relates to a complex consisting them.

Abstract: The invention provides new methods for preparation of cyclic oxygen compounds, including 2,5-disubstituted tetrahydrofurans, 2,6-disubstituted tetrahydropyrans, 2,7-disubstituted oxepanes and 2,8-oxocanes. The invention also provides new cyclic oxygen compounds and pharmaceutical compositions and therapeutic methods that comprise such compounds.

Abstract: 2,5-Diaryl tetrahydrofurans, 2,5-diaryl tetrahydrothiophenes, 1,3-diaryl cyclopentanes are disclosed that reduce the chemotaxis and respiratory burst leading to the formation of damaging oxygen radicals of polymorphonuclear leukocytes during an inflammatory or immune response. The compounds exhibit this biological activity by acting as PAF receptor antagonists, by inhibiting the enzyme 5-lipoxygenase, or by exhibiting dual activity, i.e., by acting as both a PAF receptor antagonist and inhibitor of 5-lipoxygenase. Also disclosed is a method to treat disorders mediated by PAF and/or leukotrienes that includes administering an effective amount of one or more of the above-identified compounds or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier, to a patient in need of such therapy.

Abstract: The present invention relates to novel hydantoin compounds represented by formula (I) which shows an inhibitory activity against farnesyl transferase, and thus can be used as an anti-cancer agent, or pharmaceutically acceptable salts thereof, in which R1, R2, R3 and R4 are as defined in the present application. The present invention also relates to a process for preparation of the compound of formula (I), and to an anti-cancer composition comprising the compound of formula (I) as an active ingredient.

Abstract: The present invention relates to a high-resistivity carbon black coated with a resin on the surface and having a volume resistivity of not less than 100 &OHgr;·cm.

Abstract: Hollow carbon microcoils are provided having a pitch that is substantially zero. Also provided are ceramic microcoils comprising a metal nitride, a metal carbide or a metal carbonitride. The invention also includes methods for producing such microcoils.

Abstract: The present invention relates to an enteric coated granule prepared by coating lactic acid bacteria-containing seed with a water-miscilble coating material and then, if desired, subjecting the first coated product to the second coating with a controlled-release coating material.

Abstract: The invention relates to a novel anilide compound and a pharmaceutical composition comprising the same. The invention relates to a compound represented by the following general formula: represents a divalent residue of benzene with a substituent(s), heterocycle-condensed benzene which may or may not have a substituent, pyridine which may or may not have a substituent, cyclohexane or naphthalene or Ar represents an aryl group which may or may not have a substituent; X represents —NH—, oxygen atom or sulfur atom; Y represents —NR4—, oxygen atom, sulfur atom, sulfoxide or sulfone; Z represents single bond or —NR5—; R4 represents hydrogen atom, a lower alkyl group, an aryl group or a silylated lower alkyl group which may or may not have a substituent; R5 represents hydrogen atom, a lower alkyl group, an aryl group or a silylated lower alkyl group which may or may not have a substituent; and n represents an integer of 0 to 15.

Abstract: The present invention is related to a method for preparing lactam represented by the following formula: wherein R is C2-10 alkylene which may be optionally substituted with C1-6 alkyl or phenyl; R′ is a hydrogen atom, C1-6 alkyl, C1-6 hydroxyalkyl or phenyl. The method for preparing lactam comprises an amination reaction using crystalline aluminosilicate zeolites as catalysts under the condition of gas phase in the presence of (a) lactone, (b) amine and/or ammonia and (c) water.

Abstract: A monoclonal antibody that specifically recognizes phosphatidylinositol-3,4,5-triphosphate (PIP3) but does not cross-react with structurally similar phospholipid antigens is advantageous for PIP3-specific immunoassay. The gene in the variable regions of the monoclonal antibody has been identified, which enables producing recombinant antibodies.

Abstract: An oil-in-water emulsion for application on a skin surface is disclosed. The emulsion comprises an oily phase and an aqueous phase. The oily phase comprises a first lipid of vegetable or animal origin. The emulsion is stabilized by containing at least one surfactant/emulsifier. The surfactant/emulsifier is substantially removed from a skin surface onto which the emulsion has been applied and from the emulsion by flushing with a liquid, thereby leaving at least a part of the oily phase on the skin. When the emulsion is diluted with tap water, which has a degree of hardness of about 18 degrees in a volume of 100 parts of water to one part of the emulsion at ambient temperature, it is separated into at least two distinct phases after standing for 24 hours at ambient temperature. The emulsion has a pH value of at least about 6 and at least about 50% w/w of the total concentration of the surfactant/emulsifier which is a fatty acid derivative.

Abstract: The present invention relates to a collagen gel, its production process, a medical material in which it is used or a kit for its production, wherein said collagen gel is obtained by crosslinking collagen with polyanion and carbodiimide.

Abstract: The present invention relates to a polyethoxylated retinamide derivative represented by formula (I), which is useful as an agent for inhibiting skin aging; in R represents hydrogen or C1-6 lower alkyl and n denotes the number of 2 to 100, and the process for preparing the compound of formula (I) as an effective component.